source
- Antheia secures $80 million conditional loan from DOD to expand U.S. generic drug manufacturingAntheia, a biosynthesis manufacturer, has been awarded a conditional loan of $80 million from the U.S. Department of Defense. The funding is aimed at onshoring the company’s generic drug productio…
- EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnershipEyePoint, a Watertown, Massachusetts biotech, reported that its experimental therapy did not meet primary endpoints in a Phase 3 study, marking a setback for the company. Following the trial failu…